Cellnovo to cease producing its insulin pumps and technology

Cellnovo, a company that made innovative insulin pump and diabetes management systems, has announced it will cease production of its systems.
The company, which has its offices in Bridgend and Paris, has called in administrators to restructure the company’s activities.
Sophie Baratte, Chief Executive Officer of Cellnovo, said: “This is not a decision that was taken lightly but it is the only option that is available to us today. Our biggest priority has always been patients’ well-being and we will continue to do our utmost to support a smooth transition for patients and clinicians.”
The Cellnovo System included a small pump that could be worn as a patch pump and required only a very short amount of tubing. This helped to reduce some of the problems associated longer tubing, such as getting caught or snagged.
The Cellnovo System was the world’s first mobile diabetes management system that included an insulin pump, activity monitor and a wireless, touchscreen handset with connectivity to secure servers.
The data, sent to a secure online management portal, meant the user, clinicians and parents could monitor the condition when needed.
Sophie Baratte added: “We are grateful to all those who helped us to bring our innovative diabetes management platform to the market, particularly the clinicians and patients who believed in the benefits of this novel system.
“We are also thankful to our distributors and partners who shared our passion and brought their professionalism to the service of our commercial activities. Unfortunately, we were unable to withstand the pressures of the competitive environment and the challenges of rolling-out a breakthrough system at a sustainable cost.”
The loss of Cellnovo as an insulin pump manufacturer follows the loss of Animas, who announced their exit from the insulin pump business in October 2017.